PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study documents failure rate of antibiotic treatment for gonorrhea

2013-01-09
(Press-News.org) CHICAGO – In an examination of the effectiveness of cefixime, the only oral cephalosporin antimicrobial recommended for treatment of Neisseria gonorrhoeae (gonorrhea) infections, researchers found a clinical treatment failure rate of nearly 7 percent for patients treated at a clinic in Toronto, according to a preliminary study published in the January 9 issue of JAMA.

"Because of Neisseria gonorrhoeae resistance to all prior first-line antimicrobial agents, cephalosporin [antibiotic] therapy with adjuvant azithromycin or doxycycline is recommended for treatment of gonorrhea," according to background information in the article. Cefixime is the only oral cephalosporin recommended for gonorrhea treatment. "An increase in the minimum inhibitory concentration [MIC; lowest concentration of an anti-microbial agent that will prevent the growth of an organism] of N. gonorrhoeae to cefixime, and to a lesser extent, an intramuscularly administered cephalosporin, ceftriaxone, has been identified in cultured isolates worldwide. The World Health Organization has sounded alarms for the threat of untreatable gonorrhea."

Vanessa G. Allen, M.D., M.P.H., of Public Health Ontario, Toronto, Canada, and colleagues conducted a study to determine whether N. gonorrhoeae strains with reduced susceptibilities to cefixime are associated with clinical failures. The study group consisted of N. gonorrhoeae culture-positive individuals identified between May 2010 and April 2011 and treated at a sexual health clinic in Toronto with cefixime as recommended by Public Health Agency of Canada guidelines. The primary outcome measure for the study was cefixime treatment failure, defined as the repeat isolation of N. gonorrhoeae at the test-of-cure visit identical to the pretreatment isolate by molecular typing and explicit denial of re-exposure.

There were 291 N. gonorrhoeae culture-positive individuals identified. Of 133 who returned for test of cure, 13 were culture positive; 9 patients were determined to have experienced cefixime treatment failure, with an overall rate of clinical treatment failure of 6.77 percent. The rate of clinical failure associated with a cefixime MIC of 0.12 μg/mL or greater was 25 percent compared with 1.90 percent of infections with cefixime MICs less than 0.12 μg/mL.

"This study presents the first series of clinical failures of gonorrhea associated with the use of cefixime in North America, identified by the concurrent strategies of routine test-of-cure and culture-based testing for N. gonorrhoeae," the authors write.

"In light of the increases in cefixime MICs among isolates of N. gonorrhoeae across North America, this study offers preliminary clinical data to support the recent CDC recommendations that cefixime is no longer optimal first-line therapy for the successful treatment of gonorrhea. As elevated MICs to ceftriaxone are also emerging, albeit at 1 to 2 MIC dilutions less than the cefixime MIC, proactive strategies for the identification of clinical failures of N. gonorrhoeae to this last commercially available agent are required."

(JAMA. 2013;309(2):163-170; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Editorial: Cephalosporin-Resistant Gonorrhea in North America

In an accompanying editorial, Robert D. Kirkcaldy, M.D., M.P.H., of the Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, and colleagues write that the findings of this study, of documented cephalosporin treatment failures in North America, although expected, "its arrival is deeply troubling; clinicians now face the emergence of cephalosporin-resistant N. gonorrhoeae without any well-studied, effective backup treatment options."

"New antibiotics for treating gonococcal infections are needed. A clinical trial sponsored by the National Institute of Allergy and Infectious Diseases examining novel combinations of existing drugs just completed enrollment, and a small study of a new oral agent is ongoing. But the antibiotic pipeline is running dry: continued investment in antibiotic development is critical. Meanwhile, the gonococcus has continued to develop the capability to defeat each new antibiotic used. The threat of drug-resistant gonorrhea is increasing and has reached North America. Clinicians, drug developers, and public health professionals must act now."

(JAMA. 2013;309(2):185-187; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

###

To contact Vanessa G. Allen, M.D., M.P.H., call Nicole Helsberg at 647-260-7466 or email nicole.helsberg@oahpp.ca. To contact editorial author Robert D. Kirkcaldy, M.D., M.P.H., call the NCHHSTP Media Office at 404-639-8895 or email NCHHSTPMediaTeam@cdc.gov.

END



ELSE PRESS RELEASES FROM THIS DATE:

Post-operative intravenous acetaminophen may help reduce use of morphine in infants

2013-01-09
CHICAGO – Among infants undergoing major surgery, postoperative use of intermittent intravenous paracetamol (acetaminophen) for the management of pain resulted in a lower cumulative morphine dose over 48 hours, according to a study appearing in the January 9 issue of JAMA. Opioid therapy for the treatment of pain is associated with adverse effects. Researchers are seeking alternative analgesic regimens in neonates and infants, according to background information in the article. Paracetamol has been proposed as an alternative, with one study showing promise. Ilse Ceelie, ...

Lung cancer patients live longer if they use beta-blockers while receiving radiotherapy

2013-01-09
Patients with non-small-cell lung cancer survive longer if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients published in the cancer journal Annals of Oncology [1] today (Wednesday). Researchers at the University of Texas MD Anderson Cancer Center (Houston, USA) reviewed the progress and outcomes of patients who had received radiotherapy as their main or first line of treatment for cancer (known as "definitive radiotherapy" i.e. radiotherapy that is delivered at doses of 60 Gy or more, with the intention of curing the disease). ...

Cheating slime mold gets the upper hand

Cheating slime mold gets the upper hand
2013-01-09
A 'cheater' mutation (chtB) in Dictyostelium discoideum, a free living slime mould able to co-operate as social organism when food is scarce, allows the cheater strain to exploit its social partner, finds a new study published in BioMed Central's open access journal BMC Evolutionary Biology. The mutation ensures that when mixed with 'normal' Dictyostelium more than the fair share of cheaters become spores, dispersing to a new environment, and avoiding dying as stalk cells. Dictyostelium have an unusual life style. They generally live as individual amoeboid cells, eating ...

Triple mix of blood pressure drugs and painkillers linked to kidney problems

2013-01-09
Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on bmj.com today. Although the absolute risk for individuals is low, it is still something doctors and patients should be aware of, say the researchers. Acute kidney injury (also known as kidney failure) is a major public health concern. It occurs in more than 20% of hospital inpatients and is associated with around half of all potentially preventable deaths in hospital. ...

Cancer screening unlikely to benefit patients with a short life expectancy

2013-01-09
Breast and colorectal cancer screening should be targeted towards patients with a life expectancy greater than 10 years: for any shorter life expectancy the harms are likely to outweigh the benefits, concludes a study published on bmj.com today. The authors stress that their results "should not be used to deny screening for patients with limited life expectancy" but "should inform decision making which aims to account for patient preferences and values while maximising benefits and minimising risks." Guidelines recommend screening healthy older patients because complications ...

BMJ raises concerns over the effectiveness of a costly and invasive procedure for melanoma

2013-01-09
A special report published by the BMJ today finds that thousands of melanoma patients around the world are undergoing an expensive and invasive procedure called sentinel node biopsy, despite a lack of clear evidence and concerns that it may do more harm than good. Although not recommended for routine use in England, it has become the standard care for melanoma patients in several countries including the United States, where it was estimated to cost over $686m in 2012. Melanoma is the fifth most common cancer in the UK, affecting one in 60 people. In the US it affects ...

Reduction in air pollution from wood stoves associated with significantly reduced risk of death

2013-01-09
Male deaths from all-causes, but particularly cardiovascular and respiratory disease, could be significantly reduced with a decrease in biomass smoke (smoke produced by domestic cooking and heating and woodland fires), a paper published today on bmj.com suggests. The researchers say this could have significant impact on further interventions to reduce pollution from this source. Although a large amount of research has been carried out on the adverse health effects of air pollution, no studies have reported reductions in deaths associated with interventions to reduce ...

First oral drug for spinal cord injury improves movement in mice, study shows

2013-01-09
COLUMBUS, Ohio – An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows. The compound efficiently crossed the blood-brain barrier, did not increase pain and showed no toxic effects to the animals. "This is a first to have a drug that can be taken orally to produce functional improvement with no toxicity in a rodent model," said Sung Ok Yoon, associate professor of molecular & cellular biochemistry at Ohio State University and lead author of the study. "So far, in the spinal cord ...

Synthetic 'poop' can cure C. difficile infection, study finds

2013-01-09
A synthetic "poop" developed at the University of Guelph can cure nasty gastrointestinal infections caused by Clostridium difficile, a toxin-producing bacterium. A study on the artificial stool was published today in the inaugural issue of Microbiome, a new peer-reviewed science journal. The stool – a "super-probiotic" called RePOOPulate – was created by Guelph microbiologist Emma Allen-Vercoe to replace human fecal matter used in stool transplants, a known treatment for C. difficile. She made the super-probiotic from purified intestinal bacterial cultures grown ...

Earth-size planets common in galaxy

Earth-size planets common in galaxy
2013-01-09
An analysis of the first three years of data from NASA's Kepler mission, which already has discovered thousands of potential exoplanets, contains good news for those searching for habitable worlds outside our solar system. It shows that 17 percent of all sun-like stars have planets one to two times the diameter of Earth orbiting close to their host stars, according to a team of astronomers from the University of California, Berkeley, and the University of Hawaii at Manoa. This estimate includes only planets that circle their stars within a distance of about one-quarter ...

LAST 30 PRESS RELEASES:

Scientists target ‘molecular machine’ in the war against antimicrobial resistance

Extending classical CNOP method for deep-learning atmospheric and oceanic forecasting

Aston University research: Parents should encourage structure and independence around food to support children’s healthy eating

Thunderstorms are a major driver of tree death in tropical forests

Danforth Plant Science Center adds two new faculty members

Robotic eyes mimic human vision for superfast response to extreme lighting

Racial inequities and access to COVID-19 treatment

Residential segregation and lung cancer risk in African American adults

Scientists wipe out aggressive brain cancer tumors by targeting cellular ‘motors’

Capturability distinction analysis of continuous and pulsed guidance laws

CHEST expands Bridging Specialties Initiative to include NTM disease and bronchiectasis on World Bronchiectasis Day

Exposure to air pollution may cause heart damage

SwRI, UTSA selected by NASA to test electrolyzer technology aboard parabolic flight

Prebiotics might be a factor in preventing or treating issues caused by low brain GABA

Youngest in class at higher risk of mental health problems

American Heart Association announces new volunteer leaders for 2025-26

Gut microbiota analysis can help catch gestational diabetes

FAU’s Paulina DeVito awarded prestigious NSF Graduate Research Fellowship

Champions for change – Paid time off initiative just made clinical trials participation easier

Fentanyl detection through packaging

Prof. Eran Meshorer elected to EMBO for pioneering work in epigenetics

New 3D glacier visualizations provide insights into a hotter Earth

Creativity across disciplines

Consequences of low Antarctic sea ice

Hear here: How loudness and acoustic cues help us judge where a speaker is facing

A unique method of rare-earth recycling can strengthen the raw material independence of Europe and America

Epilepsy self-management program shows promise to control seizures, improve mood and quality of life

Fat may play an important role in brain metabolism

New study finds no lasting impact of pandemic pet ownership on human well-being

New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects

[Press-News.org] Study documents failure rate of antibiotic treatment for gonorrhea